Tenpoint Therapeutics, a biotech company developing treatments for age-related vision loss, announced on January 29, 2026, that it has raised $235 million in Series B funding to support the US commercial launch of YUVEZZI, its presbyopia eye drop recently approved by the FDA. The round was led by Janus Henderson with participation from EQT Nexus, Hillhouse, and the British Business Bank.
Presbyopia is an age-related condition affecting the eye’s ability to focus on close objects, typically becoming noticeable in people over 40. Current management approaches include reading glasses, progressive lenses, or invasive surgical procedures like LASIK or lens implants. YUVEZZI represents a non-invasive pharmacological alternative using a dual-agent formula that temporarily improves near vision.
The FDA approval positions YUVEZZI as first-of-its-kind pharmacological treatment for presbyopia available in the United States. While the specific mechanism has not been fully disclosed, the dual-agent approach likely works by modulating pupil size and depth of field, allowing improved near vision without compromising distance vision. Clinical trials demonstrated statistically significant improvements in near vision within hours of administration, with effects lasting several hours.
The market opportunity is substantial. Approximately 128 million Americans have presbyopia, with the condition affecting virtually everyone by age 50. The global presbyopia treatment market is projected to reach tens of billions of dollars as aging populations in developed countries increase the addressable patient population.
The $235 million Series B funding will primarily support commercial launch activities including scaling manufacturing to meet anticipated demand, building specialty pharmaceutical distribution relationships, conducting physician education programs to drive awareness and adoption, funding direct-to-consumer marketing campaigns, and supporting insurance coverage and reimbursement negotiations to maximize patient access.
Tenpoint’s commercial strategy targets both the medical establishment and consumer marketing. On the physician side, the company will engage ophthalmologists and optometrists through professional education highlighting clinical trial results and appropriate patient selection criteria. On the consumer side, direct-to-consumer advertising will build awareness among presbyopic patients who may request the treatment from their eye care providers.
Pricing strategy will balance premium positioning reflecting innovative pharmacological approach with accessibility considerations to maximize patient uptake. While specific pricing has not been disclosed, analogs in the specialty pharmaceutical space suggest annual treatment costs could range from hundreds to low thousands of dollars depending on usage frequency, positioning between commodity reading glasses but below surgical procedures.
Regulatory approval in international markets represents another growth opportunity. Tenpoint has indicated plans to pursue regulatory approvals in Europe, Japan, and other major markets where aging demographics create similar demand dynamics to the United States. Successful international expansion could significantly increase addressable market and revenue potential.
Competitive dynamics will evolve as other pharmaceutical companies observe YUVEZZI’s market reception. Multiple companies are developing alternative pharmacological presbyopia treatments at various clinical trial stages. Additionally, advances in refractive surgery technology and emerging approaches like corneal inlays create alternative treatment modalities.
Risk factors include patient adoption rates if eye drops require frequent administration, potential side effects limiting suitable patient populations, reimbursement challenges if insurance coverage proves limited, and competition from both existing reading glasses and future pharmacological alternatives. However, the unmet need for convenient, non-invasive presbyopia treatment creates significant opportunity if YUVEZZI delivers on clinical promise in real-world use.
